Device type · QRA
Virtual Reality Behavioral Therapy Device For Pain Relief
Last checked: Nov 19, 2026Source: openFDAMethods & limitations
Product code
QRA
Physical Medicine
Device class
Class II
FDA decisions since 2015
6
510(k), De Novo and PMA
Adverse event reports
0
Received Nov 1, 2025 to Nov 19, 2026
How FDA classifies it
- Device type
- Virtual Reality Behavioral Therapy Device For Pain Relief
- Product code
- QRA
- Device class
- Class II
- Review panel
- Physical Medicine
- Regulation
- 21 CFR 890.5800
- Specialty
- Physical Medicine & Rehabilitation
- FDA record
- Classification database entry for QRA
Latest FDA decisions
- VRNT510(k)
K254004 · Decided Apr 10, 2026 · 116 days after receipt
Device type: Virtual Reality Behavioral Therapy Device For Pain Relief (QRA) · Neurology & Neurosurgery
- RelieVRx (Pico G3)510(k)
K251519 · Decided Aug 13, 2025 · 89 days after receipt
Device type: Virtual Reality Behavioral Therapy Device For Pain Relief (QRA) · Neurology & Neurosurgery
- RelieVRx510(k)
K243417 · Decided Dec 4, 2024 · 30 days after receipt
Device type: Virtual Reality Behavioral Therapy Device For Pain Relief (QRA) · Neurology & Neurosurgery
3 more FDA decisions with a free account
Reports received
0
Received Nov 1, 2025 to Nov 19, 2026
Malfunction reports
0
Injury reports
0
Death reports
0
Adverse event reports received per month
By the date FDA received each report, stacked by event type. The newest month is incomplete.
No reports to chart for this view.
Manufacturers named most often
Last 12 months. Bigger sellers get more reports. This is not a ranking of safety.
No manufacturers to rank.
Device problems as coded
Last 12 months. FDA's terms. A report can carry several.
No device problems coded.
Patient problems as coded
Last 12 months. FDA's terms. A report can carry several.
No patient problems coded.
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-2044-2023 · Started Feb 27, 2023 · Posted by FDA Jun 30, 2023
Reason given: There is the potential for the program software to malfunction which will not allow it to move forward to the next session.
Cause as FDA categorized it: Software Manufacturing/Software Deployment
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.